[Molsidomine in ergometric tests (author's transl)].

Area of Science:

• Cardiology
• Pharmacology

Background:

• Stable angina pectoris is a common cardiovascular condition characterized by chest pain due to myocardial ischemia.
• Exercise electrocardiography (ECG) is a standard tool for diagnosing and assessing the severity of angina.

Purpose of the Study:

• To evaluate the efficacy of sublingual molsidomine in patients with stable angina pectoris.
• To correlate the pharmacological effects of molsidomine with exercise performance and ECG changes.

Main Methods:

• A double-blind, cross-over study involving 9 patients with stable angina pectoris.
• Administration of 2 mg sublingual molsidomine compared to placebo.
• Assessment of exercise tolerance (Watt-minute product) and ST-segment depression during bicycle ergometry.
• Measurement of blood plasma levels of molsidomine.

Main Results:

• Molsidomine increased maximal Watt-minute product (exercise tolerance) significantly for over 5 hours.
• ST-segment lowering during exercise was reduced by molsidomine, with effects lasting up to 3 hours.
• Blood plasma levels of molsidomine correlated with its therapeutic action, showing a peak effect at 1.5 hours and a half-life of 2.03 hours.

Conclusions:

• Sublingual molsidomine is effective in improving exercise capacity and reducing ischemic ECG changes in patients with stable angina pectoris.
• The drug's action is dose-dependent and correlates with plasma concentrations.
• Molsidomine represents a viable therapeutic option for managing stable angina.